Navigation Links
Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV™ (acetaminophen) Injection
Date:1/18/2011

SAN DIEGO, Jan. 18, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced the launch of OFIRMEV™ (acetaminophen) injection, the first and only intravenous (IV) formulation of acetaminophen to be approved in the United States.  The U.S. Food and Drug Administration (FDA) approved OFIRMEV in November 2010 for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever.  OFIRMEV is now available to hospitals across the U.S.  

"With the launch of OFIRMEV, physicians will have access to the first new class of IV pain medication in nearly two decades," said Ted Schroeder, president and CEO of Cadence.  "Our focus now turns to working closely with hospitals and physicians to expand access and utilization and establish OFIRMEV as a foundational therapy in the management of pain in hospitalized patients.  At this initial stage of commercialization, we are pleased with the early signals of physician demand and formulary access.  We anticipate that by the end of this year OFIRMEV will be on formulary at approximately 800 - 1,000 hospitals, which will represent approximately half of the IV analgesic opportunity."

The national launch of OFIRMEV is being supported by 147 hospital sales specialists and 13 field medical science liaisons.  These field personnel have extensive hospital experience and have completed rigorous training in preparation for the launch.  Through agreements with the three major pharmaceutical wholesalers, distribution centers across the U.S. are fully stocked and accepting orders from hospitals.  

Until now, the only injectable drugs available to treat pain and fever were opioids and NSAIDs.  When used as part of a multi-modal approach to pain management in placebo-controlled clinical stu
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
2. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
3. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
4. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
5. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
6. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
7. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... --  SunTrust Robinson Humphrey (STRH) today announced ... equity research team in biotechnology and oilfield services.  ... research demonstrates our commitment to providing our valued ... investment decision making," said Biff Woodruff , ... make significant investments in differentiated content at a ...
(Date:8/28/2014)... Aug. 28, 2014  Armetheon, Inc. ( www.armetheon.com ... mid- to late-stage cardiovascular drug candidates, today announced ... first round of financing. The Series A round ... Bioventures with participation from investors that included Atheneos ... Dr. Larry Hsu , the founder of ...
(Date:8/28/2014)... August 27, 2014 Scientists, researchers, and ... SPIE Laser Damage 2014 symposium. Marking its ... high-power lasers will run 14-17 September. The event is ... and photonics . , The premier conference for basic ... damage to optical materials will engage researchers and engineers ...
(Date:8/28/2014)... August 28, 2014 Earlier this month, ... in partnership with the U.S. Air Force on ... The results indicated that this type of fuel made ... and will be important to America’s Eco friendly future. ... has a mandate to become independent of foreign oil ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5
... mimicking a brick-and-mortar molecular structure found in seashells, University ... strong as steel but lighter and transparent. , ... water-soluble polymer that shares chemistry with white glue. , ... but the new material isn,t quite stretchy enough to ...
... with,its third quarter 2007 earnings release (expected to be issued ... ) is pleased to invite you to,listen to its quarterly ... on Thursday, October 25 at 9:00 a.m. ET. What: ... Presentation When: October 25, 2007, 9:00 a.m. ...
... Oct. 4 Coherent, Inc.,(Nasdaq: COHR ) today ... an additional NASDAQ Staff Determination letter indicating that,the Company ... set forth in Marketplace Rules 4350(e) and 4350(g) due ... during its fiscal,year ended September 30, 2007. The notice ...
Cached Biology Technology:U-M research: New plastic is strong as steel, transparent 2Coherent, Inc. Receives Expected Letter from NASDAQ 2
(Date:8/28/2014)... are healthier for your neighbors than traditional cigarettes, ... to a new study from USC. , Scientists ... 10-fold decrease in exposure to harmful particles, with ... exposure to some harmful metals in second-hand e-cigarette ... While tobacco smoke contains high levels of polycyclic ...
(Date:8/28/2014)... (August 28, 2014) Researchers at the University of ... muscular dystrophy (FSHD) to be used for muscle regeneration ... potential therapies for FSHD. , The research is published ... Reports . , There is no treatment for FSHD, ... common type of muscular dystrophy. FSHD is an unusual ...
(Date:8/28/2014)... developmental on-off switch for Streptomyces , a group ... the world,s naturally derived antibiotic medicines. , Their ... possible to manipulate this switch to make nature,s antibiotic ... 28 in Cell , found that a unique ... larger protein called BldD ultimately controls whether a bacterium ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2UMN researchers find animal model for understudied type of muscular dystrophy 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... remains a devastating problem in Africa and understanding the ... the effort to combat the disease. A new study ... conducted in Western Kenya by Jacob Koella and colleagues ... with the infectious stages of malaria than to those ...
... warfarin to prevent harmful clotting after a heart attack, stroke, ... vary greatly and can be hard to predict. Some of ... involved in blood clotting, according to a new study published ... of Medicine. , By looking at the genetic makeup of ...
... of Utah researchers showed that a fruit fly gene ... into adults, and how the transformation initially proceeds. Understanding ... children become surly teenagers. , When the DHR4 gene ... an immature larva to a sexually active adult. It ...
Cached Biology News:Mosquitoes are more attracted to individuals infected with malaria 2Genetic variation alters response to common anti-clotting drug 2Genetic variation alters response to common anti-clotting drug 3Scientists find a maturity gene in fly 2Scientists find a maturity gene in fly 3Scientists find a maturity gene in fly 4
Rabbit polyclonal to DcR2 ( Abpromise for all tested applications). entrezGeneID: 8793 SwissProtID: Q9UBN6...
...
...
Mouse Amphiregulin MAb (Clone 206220)...
Biology Products: